Source link : https://www.newshealth.biz/health-news/long-acting-injection-better-for-prep-in-men-gender-diverse-groups/
Twice-yearly lenacapavir (Sunlenca) substantially reduced HIV infection when used for preexposure prophylaxis (PrEP) in cisgender men and transgender or gender-nonbinary persons in the pivotal PURPOSE 2 trial. Injections every 26 weeks cut the rate of HIV infections by a relative 89% compared with daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF, Truvada), with rates of 0.10 versus […]
Author : News Health
Publish date : 2024-11-27 22:00:00
Copyright for syndicated content belongs to the linked Source.